Zymeworks rises as ovarian cancer drug gets FDA fast-track status

Shares of biotech firm Zymeworks ZYME.O rise 3% to $24.90 premarket

Co says U.S. FDA has granted Fast Track status to its experimental drug ZW191 for advanced ovarian cancer, a disease where tumors no longer respond to standard platinum-based chemotherapy

Adds drug is being tested in an early-stage study to assess safety and early signs of benefit in patients with advanced solid tumors

ZW191 is an experimental antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells carrying folate receptor‑alpha, commonly found in aggressive ovarian tumors - ZYME

Co says FDA decision applies regardless of patients’ protein levels, which could allow broader use if approved

Fast Track is meant to speed development and regulatory review for drugs targeting serious conditions with limited treatment options

Shares rose ~80% in 2025